Frailty Index and Geriatric Assessment in Predicting Toxicity to Front-Line Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

NCT01026467 · clinicaltrials.gov ↗

COMPLETED

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Non-small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer

Interventions

DRUG: cisplatin
DRUG: carboplatin
OTHER: questionnaire administration

Sponsor

Wake Forest University Health Sciences

Collaborators

[object Object]